Glaucoma, Graft Failure, Intraocular Pressure
Conditions
Keywords
glaucoma, glaucoma surgery, patch graft, intraocular pressure
Brief summary
This was a retrospective, non-comparative study of 100 eyes of 100 consecutive glaucoma patients who had undergone glaucoma drainage device implantation (Baerveldt shunt) during January 2006 to December 2016. Glycerin-preserved, human-donor, corneoscleral tissue was used as a patch graft to cover the tube portion of the GDD over the sclera. The patch graft related complication was comparable to the previous reports using conventional sclera or pericardium.
Detailed description
This retrospective, non-comparative study was conducted at the Department of Ophthalmology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand. The medical records of consecutive patients who had undergone glaucoma drainage device implantation employing the fornix-based conjunctival flap technique and using a glycerin-preserved, human-donor, corneoscleral graft. The procedures were carried out by, or under the supervision of, one surgeon (NK) between January 2006 and December 2016 were reviewed. The study protocol was approved by the Siriraj Institutional Review Board, Faculty of Medicine, Siriraj Hospital, Mahidol University.
Interventions
BIOLOGICALglaucoma drainage device implantation
Glaucoma drainage device implantation, a 350 mm2 Baerveldt (BG 101-350) GDD (Johnson and Johnson, Santa Ana, CA, USA) was performed using glycerin-preserved, human-donor, corneoscleral tissue ( the remaining from a heterologous, human-donor corneal button, obtained from the International Eye Bank of Thailand, after a clear corneal graft had been used for penetrating keratoplasty.) The tissue had been preserved in glycerin using the sterile technique and kept in a medical refrigerator for no longer than 6 months.
Sponsors
Siriraj Hospital
Study design
Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Consecutive patients who had undergone glaucoma drainage device implantations between January 2006 and December 2016 at Siriraj hospital by or under supervision of one surgeon (NK). 2. The GDD implantation using glycerin-preserved, human-donor, corneoscleral tissue as a patch graft
Exclusion criteria
1.Patients who had follow-up period less than 12 months after operation.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Numbers of eyes with graft related complication | Postoperative period from January 3, 2006 to August 31, 2019 | Numbers of eyes with the patch-graft related complications included tube exposure, infection, leaking, etc |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Intraocular pressure | preoperative and postoperative period from January 3, 2006 to August 31, 2019 | The intraocular pressure level (must be less than 21 mmHg.) |
| numbers of medication | Postoperative period from January 3, 2006 to August 31, 2019 | Numbers of post-operative anti-glaucoma medication comparing to pre-operative medications |
| Visual acuity | Postoperative period from January 3, 2006 to August 31, 2019 | The level of post-operative visual acuity compared to pre-operative visual acuity |
| Numbers and types of post-operative intervention | Postoperative period from January 3, 2006 to August 31, 2019 | Numbers and types of post-operative intervention to correct the complication |
Countries
Thailand
Outcome results
None listed